NCT06190067View on ClinicalTrials.gov

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Relapsed Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Interventions
DRUG

Azacitidine Plus PD-1 therapy

Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)

Trial Locations (1)

100048

RECRUITING

Navy General Hospital, Beijing

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER